Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 5.55Strides Pharma Science Ltd, operating in the Healthcare Services sector, shows a mixed financial performance. The company demonstrates good solvency, driven by its equity ratio. Growth is a mixed bag, with strong revenue and operating profit growth offset by declines in EPS, asset growth, and net income. While interest coverage is adequate, dividend coverage is weak. Profitability metrics present a contrasting picture, with strong gross profit and operating margins. Liquidity and efficiency ratios are generally weak, indicating potential challenges in short-term obligations and asset utilization. A crucial factor to consider is the variability in the pharmaceutical industry, impacting revenue streams and profitability.
Health Score : 5.55Strides Pharma Science Ltd, operating in the Healthcare Services sector, shows a mixed financial performance. The company demonstrates good solvency, driven by its equity ratio. Growth is a mixed bag, with strong revenue and operating profit growth offset by declines in EPS, asset growth, and net income. While interest coverage is adequate, dividend coverage is weak. Profitability metrics present a contrasting picture, with strong gross profit and operating margins. Liquidity and efficiency ratios are generally weak, indicating potential challenges in short-term obligations and asset utilization. A crucial factor to consider is the variability in the pharmaceutical industry, impacting revenue streams and profitability.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
51.42
Industry Median
26.02
Small Cap Median
24.30
P/E RATIO
16.97
P/B RATIO
3.04
Industry Median
4.68
Small Cap Median
5.57
P/S RATIO
1.83
Industry Median
2.28
Small Cap Median
2.94
Others
PEG RATIO
0.98
EV/EBITDA RATIO
8.83
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1024.2 as on Sep 1, 2026.
Growth Score : 5.20The company demonstrates mixed growth performance. Revenue and operating profit growth are strong, indicating successful market penetration and operational improvements. However, earnings per share, asset growth, and net income growth are weak.
Revenue Growth RateExcellentOperating Profit Growth RateExcellent
Earnings Per Share (EPS) GrowthPoorAsset Growth RatePoorNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -7.42 | 20.13 | 5.48 | 17.35 | 6.44 |
| Operating Profit Growth Rate | -124.39 | 210.69 | 264.14 | 52.08 | 15.19 |
| Earnings Per Share (EPS) Growth | -271.23 | 56.21 | 65.78 | 5174.87 | -84.52 |
| Asset Growth Rate | -0.42 | -4.99 | -12.06 | 2.24 | 16.83 |
| Net Income Growth Rate | -283.72 | 55.27 | 55.66 | 3927.66 | -84.02 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | FDC | 7.64 | 19.29 | Neutral | 346.00 | 17.56 | 281.00 |
| 2 | SUPRIYA | 7.46 | 30.91 | Overvalued | 294.00 | 25.98 | 209.00 |
| 3 | AARTIPHARM | 7.46 | 44.90 | Neutral | 369.00 | 19.43 | 175.00 |
| 4 | INNOVACAP | 7.36 | 43.37 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | AKUMS | 7.28 | 48.06 | Overvalued | 522.00 | 7.09 | 256.00 |
| 6 | MARKSANS | 7.24 | 34.97 | Neutral | 601.00 | 6.64 | 420.00 |
| 7 | AARTIDRUGS | 7.20 | 20.00 | Undervalued | 309.00 | 18.54 | 195.00 |
| 8 | HIKAL | 7.13 | -50.14 | Neutral | 220.00 | -3.95 | -49.00 |
| 9 | RPGLIFE | 7.12 | 37.20 | Neutral | 147.00 | 69.64 | 115.00 |
| 10 | SHILPAMED | 5.94 | 71.52 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 11 | STAR | 5.55 | 16.97 | Undervalued | 925.00 | 19.92 | 575.00 |
| 12 | JSLL | 5.52 | 28.20 | Neutral | 349.00 | 17.87 | 222.00 |
| 13 | GUFICBIO | 5.49 | 65.79 | Neutral | 151.00 | 6.30 | 64.00 |
| 14 | DCAL | 5.38 | 29.23 | Neutral | 566.00 | -2.45 | 97.00 |
| 15 | ORCHPHARMA | 4.85 | 234.05 | Neutral | 41.00 | 8.91 | 21.00 |
| 16 | SEQUENT | 4.61 | 301.49 | Overvalued | 162.00 | 1.74 | 32.00 |
| 17 | SPARC | 4.35 | 4.12 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 18 | ZOTA | 3.97 | -48.15 | Neutral | 19.00 | 8.06 | -74.00 |
| 19 | PGHL | 3.45 | 29.33 | Neutral | 466.00 | 215.00 | 357.00 |
| 20 | SANOFI | 3.45 | 17.56 | Neutral | 491.00 | 134.52 | 413.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Concall Report⬤3rd Feb 26
Q3 FY26 Earnings Conference Call
BULLISH SENTIMENT
No Stock News Available at This Moment.
Strides Pharma Science Ltd is a global pharmaceutical company with a strong presence in regulated markets, primarily the United States. It specializes in the development and manufacturing of a wide range of pharmaceutical products, including oral dosage forms, soft gel capsules, and sterile injectables. The company focuses on niche and complex products, aiming for leadership in key therapeutic areas.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Strides Pharma Science Ltd's P/E ratio (TTM) is 51.42, compared to the industry median of 26.02 and large cap median of 24.30.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Strides Pharma Science Ltd's P/B ratio is 3.04, compared to the industry median of 4.68 and large cap median of 5.57.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Strides Pharma Science Ltd's P/S ratio is 1.83, compared to the industry median of 2.28 and large cap median of 2.94.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Strides Pharma Science Ltd's PEG ratio is 0.98.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Strides Pharma Science Ltd's EV/EBITDA ratio is 8.83.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Strides Pharma Science Ltd's ROE is 18.51%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Strides Pharma Science Ltd's ROA is 13.35%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Strides Pharma Science Ltd's ROCE is 19%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Strides Pharma Science Ltd's operating margin is 19.04%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Strides Pharma Science Ltd's net margin is 11.83%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Strides Pharma Science Ltd's current ratio is 1.27.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Strides Pharma Science Ltd's debt-to-equity ratio is 0.19.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Strides Pharma Science Ltd's interest coverage ratio is 4.74.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Strides Pharma Science Ltd's DPS is ₹4.83.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Strides Pharma Science Ltd's EPS is -84.52.
(Source line: "Ratios as of 01 Sept 2026, based on last traded price of ₹1024.20. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1990 (as Strides Arcolab Limited)
Headquarters: Bengaluru, Karnataka
Core Offerings: Formulations (Orals, Softgels, Topicals), Injectables, Active Pharmaceutical Ingredients (APIs), Biotechnology products, Contract Development and Manufacturing (CDMO)
Stock Listing: NSE (STAR), BSE (532531)
Promoter: Arun Kumar / Strides Group
Strides Pharma Science Ltd was founded in 1990 as Strides Arcolab Limited. Initially focused on contract manufacturing, the company gradually expanded its presence in the regulated markets, particularly the US. Key milestones include divestment of its injectables business (Agila Specialties) to Mylan Inc. in 2013, which provided significant capital for future growth. The company then strategically rebuilt its formulations business, re-entering injectables and focusing on complex generics. In 2017, the company was renamed Strides Pharma Science Limited, reflecting its renewed focus. Currently, it operates a global manufacturing network and R&D capabilities, targeting growth in regulated and emerging markets.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceutical Business (Formulations, Injectables, Biologics) | Approx. 95% | Operating Profit |
| API Business | Approx. 5% | Operating Profit |
Formulations: This segment includes oral solids, soft gelatin capsules, topicals, and other non-sterile dosage forms. The company has a significant presence in the US market, focusing on niche and complex generic products.
Injectables: Strides re-entered the injectables space post-Agila divestment, building a strong portfolio of sterile injectables for regulated markets, leveraging its manufacturing capabilities.
API (Active Pharmaceutical Ingredients): Strides manufactures APIs primarily for captive consumption and also for external sales, supporting its formulations business.
Biotechnology: The company has a growing interest and initiatives in the biotechnology sector, particularly in biosimilars, through partnerships and internal R&D.
Arun Kumar - Founder & Whole-time Director. Mr. Kumar is a veteran in the Indian pharmaceutical industry, having founded Strides and played a pivotal role in its growth and strategic direction over three decades. He is instrumental in shaping the company's global expansion and product portfolio.
Strides Pharma Global Pte. Ltd. (Singapore)
Strides Pharma Inc. (USA)
Strides Pharma UK Ltd. (UK)
Strides Pharma Asia Pte Ltd. (Singapore)
No major recent corporate actions on record (e.g., bonus/rights issue) in the last 2-3 years. The company has historically engaged in significant M&A activities, notably the Agila Specialties divestment.
The Strides Pharma Science Ltd share price today is ₹1024.20 on NSE (STAR), as of 12 Sept 2026.
As of 01 Sept 2026, Strides Pharma Science Ltd share price is ₹1024.20, with previous close ₹1024.20. Today's range is ₹1024.20 to ₹1024.20. The 52-week range is ₹1024.20 to ₹1024.20.
As of today, Strides Pharma Science Ltd's market cap is ₹8,879.81 crore (Mid Cap).
Strides Pharma Science Ltd's current P/E ratio is 51.42, compared to the AUTOMOBILES & AUTO COMPONENTS sector average of 26.80.
Strides Pharma Science Ltd's current P/B ratio is 3.04.
Strides Pharma Science Ltd's current dividend yield is 0.47%. Last dividend of ₹0.00 per share was declared on N/A.
Strides Pharma Science Ltd's EPS (TTM) is ₹-84.52.
Strides Pharma Science Ltd is a global pharmaceutical company with a strong presence in regulated markets, primarily the United States. It specializes in the development and manufacturing of a wide range of pharmaceutical products, including oral dosage forms, soft gel capsules, and sterile injectables. The company focuses on niche and complex products, aiming for leadership in key therapeutic areas.
Strides Pharma Science Ltd is promoted by Arun Kumar / Strides Group, holding 27.91% as of 01 Sept 2026.
Strides Pharma Science Ltd is listed on NSE (STAR) and BSE (532531). Its next quarterly results are expected on August 2024 (for Q1 FY25).
Cash Earnings Per Share (Cash EPS)